

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

25<sup>th</sup> July, 2025

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Limited  
Exchange Plaza, C-1 Block-G  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Symbol: SAKAR

Dear Sir/Madam,

**Sub: Outcome of Board Meeting - Submission of Un-Audited Financial Results for the quarter ended on 30<sup>th</sup> June, 2025 and intimation of Date of Annual General Meeting, E-voting period & other matters**

We refer to our letter dated 21<sup>st</sup> July, 2025 informing the date of Meeting of the Board of Directors of the Company.

Please note that the Board of Directors of the Company ('the Board'), in their meeting held today i.e. on 25<sup>th</sup> July, 2025, *inter alia*, has taken on record the Unaudited Financial Results for the quarter ended on 30<sup>th</sup> June, 2025.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith the Statement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on 30<sup>th</sup> June, 2025 – Integrated Filing (Financial) along with Auditors' Limited Review Report thereon as **Annexure – 1**.

Further, the Board of Directors of the Company in their meeting held today, *inter alia*, has also decided to:

1. Convene the 21<sup>st</sup> Annual General Meeting ('AGM') of the Shareholders/Members of the Company on Tuesday, the 23<sup>rd</sup> September, 2025 at 1:00 P.M. through Video Conferencing ('VC')/Other Audio Visual Means ('OAVM') in compliance with the applicable provisions of the Companies Act, 2013 read with General Circular No. 9/2024 dated 19<sup>th</sup> September, 2024 read with the requirements laid down in Para 3 and Para 4 of the General Circular No.20/2020 dated 5<sup>th</sup> May, 2020 and earlier circulars issued in this regard extending relaxation by the Ministry of Corporate Affairs ('MCA circulars') read with the Securities and Exchange Board of India Circular dated 3<sup>rd</sup> October, 2024 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. provide to its Shareholders, the facility to cast their vote by electronic means i.e. 'Remote e-voting' and 'e-voting system during the AGM' on all the resolution set forth in the Notice of 21<sup>st</sup> AGM. The details of 'Remote e-voting' are given under:



1	Date & Time of commencement of Remote e-voting	at 9:00 A.M. on 20 <sup>th</sup> September, 2025
2	Date & Time of end of Remote e-voting	at 5:00 P.M. on 22 <sup>nd</sup> September, 2025
3	Cut-off date for determining rights of entitlement of Remote e-voting	16 <sup>th</sup> September, 2025
4	E-voting system during the AGM shall not be allowed beyond	15 minutes after the conclusion of AGM

The Board in their meeting held today, based on the recommendation of the Nomination and Remuneration Committee of the Company ('NRC'), also considered and approved:

- a) Appointment of Ms. Megha Samdani (DIN: 08956059) as an Independent Director of the Company for a term of five consecutive years w.e.f. 25<sup>th</sup> July, 2025 subject to approval of members/shareholders of the Company;
- b) Appointment of Ms. Reeya Kothari (DIN: 10312461) as an Independent Director of the Company for a term of five consecutive years w.e.f. 25<sup>th</sup> July, 2025 subject to approval of members/shareholders of the Company;
- c) Appointment of Ms. Hiral Patel (DIN: 09719512) as Independent Director of the Company for a term of five consecutive years w.e.f. 25<sup>th</sup> July, 2025 subject to approval of members/shareholders of the Company.

In accordance with Regulation 30 of Listing Regulations, the necessary disclosures including brief profile of above Independent Directors are as enclosed as **Annexure – 2**.

The Board, in their meeting held today, also considered and approved:

- a) Recommendation for appointment of M/s. Nishant Pandya & Associates, Practising Company Secretaries as Secretarial Auditors of the Company to conduct Secretarial Audit for a term of five (5) consecutive years commencing from FY 2025-26 to FY 2029-300, subject to shareholders approval at ensuing 21<sup>st</sup> AGM of the Company.
- b) Appointment of M/s. Dalwadi & Associates, Cost Accountants, Ahmedabad (Firm Registration No. 000338) as Cost Auditors of the Company for the F.Y. 2025-26.

The necessary disclosures under Regulation 30 of Listing Regulations are enclosed as **Annexure – 3**.

The Board, in their meeting held today, also considered and approved the appointments of following as Senior Management Personnel:

- a) Appointment of Mr. Sudhir Ghule as Chief Operating Officer (COO) of the Company with effect from 25<sup>th</sup> July 2025;
- b) Appointment of Mr. Raviraj Karia as Senior Vice President (Finance & Accounts) of the Company with effect from 25<sup>th</sup> July 2025;
- c) Appointment of Mr. Nimesh Suthar as Senior Vice President (International Business) of the Company with effect from 25<sup>th</sup> July 2025.



The necessary disclosures including brief profile under Regulation 30 of Listing Regulations is enclosed as **Annexure – 4**.

The Meeting of the Board was commenced at 11:30 a.m. and concluded at 12:10 p.m.

Kindly take the above intimations on record.

This is in due compliance of the relevant Regulations of the SEBI (LODR) Regulations, 2015.

Yours faithfully,

Date : 25<sup>th</sup> July, 2025  
Place: Ahmedabad

for **SAKAR HEALTHCARE LIMITED**  
  
  
**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**DIN: 01515296**

Encl.: As above

**STATEMENT OF STANDALONE UNAUDITED RESULTS  
FOR THE QUARTER ENDED ON 30<sup>TH</sup> JUNE, 2025**

(Rs. In Lakh)

	(Refer Notes Below)	Quarter ended on			Previous Year
		30-06-2025	31-03-2025	30-06-2024	ended on
		(Unaudited)	(Audited)	(Unaudited)	31-03-2025
					(Audited)
1	<b>Revenue from operations</b>	5273.62	5024.18	4114.77	17758.47
2	<b>Other income</b>	39.39	18.22	45.98	131.27
3	<b>Total Income (1+2)</b>	<b>5313.01</b>	<b>5042.40</b>	<b>4160.75</b>	<b>17889.74</b>
4	<b>Expenses</b>				
	a. Cost of Materials consumed	2875.73	2603.12	2249.70	9546.73
	b. Purchases of stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	19.51	(1136.00)	(43.56)	(1320.46)
	d. Employee benefits expense	754.96	1588.82	538.45	3164.85
	e. Finance costs	214.26	419.34	139.81	853.50
	f. Depreciation & amortisation expense	557.23	547.70	505.75	2088.22
	g. Other expenses	352.84	395.77	300.29	1399.03
	<b>Total Expenses</b>	<b>4774.53</b>	<b>4418.75</b>	<b>3690.44</b>	<b>15731.87</b>
5	Profit before exceptional items and tax (3-4)	<b>538.48</b>	<b>623.65</b>	<b>470.31</b>	<b>2157.87</b>
6	Exceptional items				5.14
7	Profit before tax (5-6)	538.48	623.65	470.31	2152.73
8	Tax expense:				
	Current tax	90.29	110.58	78.92	366.03
	Deferred tax	71.35	47.54	229.11	402.53
	MAT Credit Entitlement	(90.29)	(110.58)	(78.92)	(366.03)
9	<b>Profit for the period from continuing operations (7-8)</b>	<b>467.13</b>	<b>576.11</b>	<b>241.20</b>	<b>1750.20</b>
10	Profit from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	<b>Profit from Discontinuing operations (after tax) (10-11)</b>				
13	<b>Profit for the period (9+12)</b>	<b>467.13</b>	<b>576.11</b>	<b>241.20</b>	<b>1750.20</b>



# Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

(Rs. In Lakh)

Particulars	Quarter ended on			Previous Year ended on 31-03-2025
	30-06-2025	31-03-2025	30-06-2024	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>14 Other Comprehensive Income</b>				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Re-measurement gains/(losses) on defined benefit plans	(3.70)	5.71	(3.70)	(16.23)
Income tax relating to items that will not be reclassified to profit or loss	1.03	(1.58)	1.03	4.52
<i>Items that will be reclassified subsequently to profit or loss</i>				
Income tax relating to items that will be reclassified to profit or loss				
<b>Other Comprehensive Income, net of tax</b>	<b>(2.67)</b>	<b>4.13</b>	<b>(2.67)</b>	<b>(11.71)</b>
<b>15 Total Comprehensive Income for the period (13+14)</b>	<b>464.46</b>	<b>580.24</b>	<b>238.53</b>	<b>1738.49</b>
<b>16 Paid-up equity shares capital (Face Value per share Rs.10/-)</b>	<b>2224.99</b>	<b>2194.99</b>	<b>2174.99</b>	<b>2194.99</b>
<b>17 Reserves excluding Revaluation Reserves</b>				<b>26073.12</b>
<b>18 Earnings Per Share of Rs. 10/- each (for continuing operations)</b>				
- Basic	2.11	2.66	1.10	7.97
- Diluted	2.11	2.65	1.09	7.95
<b>19 Earnings Per Share of Rs.10/- each (for discontinued operations)</b>				
- Basic	0.00	0.00	0.00	0.00
- Diluted	0.00	0.00	0.00	0.00
<b>20 Earnings Per Share of Rs.10/- each (for discontinued &amp; continuing operations)</b>				
- Basic	2.11	2.66	1.10	7.97
- Diluted	2.11	2.65	1.09	7.95





**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**Notes:**

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 25 <sup>th</sup> July 2025
7	The Company has allotted 3,00,000 Equity Shares to Non-Promoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 17 <sup>th</sup> June 2025

for **SAKAR HEALTHCARE LIMITED**



**SANJAY S. SHAH**

**MANAGING DIRECTOR**

**(DIN : 01515296)**

**Date:** 25<sup>th</sup> July, 2025

**Place:** Ahmedabad

**Corporate Office:** 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007

**Phone:** 079-26584655 **Fax:** 079-26588054



**LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER  
ENDED JUNE 30, 2025**

To  
The Board of Directors  
M/s. Sakar Healthcare Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period quarter ended **30<sup>th</sup> June 2025**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").


This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W

  
Jaimin S Shah  
Partner  
Membership No. : 138488  
UDIN : 25138488BMIBAZ1456  
Place : Ahmedabad  
Date : 25.07.2025



**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED ON 30<sup>TH</sup> JUNE, 2025**

(Rs. In lakh)

Particulars	Quarter ended on			Previous Year ended on 31-03-2025
	30-06-2025	31-03-2025	30-06-2024	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
(Refer Notes Below)				
1 Revenue from operations	5273.62	5024.18	4114.77	17758.47
2 Other income	39.39	18.22	45.98	131.27
3 Total Income (1+2)	<b>5313.01</b>	<b>5042.40</b>	<b>4160.75</b>	<b>17889.74</b>
4 Expenses				
a. Cost of Materials consumed	2875.73	2603.12	2249.70	9546.73
b. Purchases of stock-in-trade	-	-	-	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	19.51	(1136.00)	(43.56)	(1320.46)
d. Employee benefits expense	754.96	1588.82	538.45	3164.85
e. Finance costs	214.26	419.34	139.81	853.50
f. Depreciation & amortisation expense	557.23	547.70	505.75	2088.22
g. Other expenses	352.84	395.77	300.29	1399.03
<b>Total Expenses</b>	<b>4774.53</b>	<b>4418.75</b>	<b>3690.44</b>	<b>15731.87</b>
5 Profit before exceptional items and tax (3-4)	<b>538.48</b>	623.65	470.31	2157.87
6 Exceptional items				5.14
7 Profit before tax (5-6)	538.48	<b>623.65</b>	470.31	2152.73
8 Tax expense:				
Current tax	90.29	110.58	78.92	366.03
Deferred tax	71.35	47.54	229.11	402.53
MAT Credit Entitlement	(90.29)	(110.58)	(78.92)	(366.03)
9 Profit for the period from continuing operations (7-8)	<b>467.13</b>	<b>576.11</b>	<b>241.20</b>	<b>1750.20</b>
10 Profit from discontinuing operations before Tax	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-
12 Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-
13 Profit for the period (9+12)	<b>467.13</b>	<b>576.11</b>	<b>241.20</b>	<b>1750.20</b>
Attributable to owner of parent	<b>467.13</b>	<b>576.11</b>	<b>241.20</b>	<b>1750.20</b>
Attributable to Non-controlling interests	-	-	-	-



**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

Particulars	Quarter ended on			Previous Year ended on 31-03-2025
	30-06-2025	31-03-2025	30-06-2024	
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>14 Other Comprehensive Income</b>				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Re-measurement gains/(losses) on defined benefit plans	(3.70)	5.71	(3.70)	(16.23)
Income tax relating to items that will not be reclassified to profit or loss	1.03	(1.58)	1.03	4.52
<i>Items that will be reclassified subsequently to profit or loss</i>				
Income tax relating to items that will be reclassified to profit or loss				
<b>Other Comprehensive Income, net of tax</b>	<b>(2.67)</b>	<b>4.13</b>	<b>(2.67)</b>	<b>(11.71)</b>
Attributable to owner of parent	(2.67)	4.13	(2.67)	(11.71)
Attributable to Non-controlling interests				
<b>15 Total Comprehensive Income for the period (13+14)</b>	<b>464.46</b>	<b>580.24</b>	<b>238.53</b>	<b>1738.49</b>
Attributable to owner of parent	464.46	580.24	238.53	1738.49
Attributable to Non-controlling interests				
<b>16 Paid-up equity shares capital (Face Value per share Rs. 10/-)</b>	<b>2224.99</b>	<b>2194.99</b>	<b>2174.99</b>	<b>2194.99</b>
<b>17 Reserves excluding Revaluation Reserves</b>				<b>26064.60</b>
<b>18 Earnings Per Share of Rs.10/- each (for continuing operations)</b>				
- Basic	2.11	2.66	1.10	7.97
- Diluted	2.11	2.65	1.09	7.95
<b>19 Earnings Per Share of Rs.10/- each (for discontinued operations)</b>				
- Basic	0.00	0.00	0.00	0.00
- Diluted	0.00	0.00	0.00	0.00
<b>20 Earnings Per Share of Rs.10/- each (for discontinued &amp; continuing operations)</b>				
- Basic	2.11	2.66	1.10	7.97
- Diluted	2.11	2.65	1.09	





**Healthcare Ltd.**

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**Notes:**

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
3	The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 25 <sup>th</sup> July 2025
7	The Company has allotted 3,00,000 Equity Shares to Non-Promoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 17 <sup>th</sup> June 2025

for SAKAR HEALTHCARE LIMITED



**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**(DIN : 01515296)**

**Date: 25<sup>th</sup> July, 2025**

**Place: Ahmedabad**



**LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER  
ENDED JUNE 30, 2025**

To  
The Board of Directors  
M/s. Sakar Healthcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended **30<sup>th</sup> June 2025** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30.06.2025, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

1) Sakar Oncology Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of Sakar Oncology Private Limited subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects, total revenues of Nil , total net profit after tax of Nil , total comprehensive income of Nil for the quarter ended June 30, 2025, as considered in the Statement. This interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
7. Our conclusion on the Statement is not modified in respect of the above matters

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W

  
Jaimin S Shah  
Partner  
Membership No. : 138488  
UDIN : 25138488BMIBBA8025  
Place : Ahmedabad  
Date : 25.07.2025



**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Statement on deviation / variation in utilisation of funds raised	
Name of listed entity	Sakar Healthcare Limited
Mode of Fund Raising	Preferential Issue (Conversion of Warrants into Equity Shares)
Date of Raising Funds	17-06-2025
Amount Raised	Rs. 8,64,00,000/-
Report filed for Quarter ended	30-06-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Not applicable
Comments of the auditors, if any	Not applicable

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30-06-2025	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Repayment/ prepayment of all or a portion of certain borrowings from State Bank of India availed by our Company	N.A.	1,54,65,000	N.A.	1,54,65,000	NIL	The Funds have been utilized in total
Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments/Utilities with electrification for Oncology unit	N.A.	7,09,35,000	N.A.	1,84,56,064	5,24,78,936	Unutilized amount will be utilized within 6 months from receipt of fund

**Deviation or variation could mean:**

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc



**C. DISCLOSURE OF OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

Not Applicable

Sr. No.	Particulars	in INR crore
<b>1.</b>	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short-term and long-term debt</b>	0

**D. DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED 30<sup>TH</sup> JUNE, 2025 (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter) :**

Not Applicable

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

:Not Applicable

Date : 25<sup>th</sup> July, 2025  
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



*Sanjay S. Shah*  
SANJAY S. SHAH  
MANAGING DIRECTOR  
DIN: 01515296

**Annexure - 2**

**Brief Profile of the Directors Appointed:**

Name of Director(s)	Ms. Megha Samdani (DIN: 08956059)	Ms. Reeya Kothari (DIN: 10312461)	Ms. Hiral Patel (DIN: 09719512)
Category of Director(s)	Independent Director	Independent Director	Independent Director
Qualification of Director	ACS, M.com	ACS, B.Com	ACS, MBA (Finance Management), LLB, B.Com (Cost & work Accountancy)
Brief profile & Experience / Expertise in Specific Functional Areas of Director	Ms. Megha Samdani holds a Bachelor degree in Commerce as well as qualified Company Secretary (ACS). Her profile includes experience in Merger and Amalgamation, Private Placement, Right issue financial restructuring and other related matters.	Ms. Reeya Kothari holds a Bachelor degree in Commerce as well as qualified Company Secretary (ACS). Her profile includes experience in Taxation, Secretarial, Legal and other related matters.	Ms. Hiral Patel holds a Bachelor degree in Commerce and Law as well as she holds degree of MBA Finance. She is also a qualified Company Secretary (ACS). Her profile includes experience of more than 7 years in Finance, Banking, Taxation Secretarial, Legal, and other related matters.
Date of Appointment	25 <sup>th</sup> July, 2025	25 <sup>th</sup> July, 2025	25 <sup>th</sup> July, 2025
Reason for change	Appointment	Appointment	Appointment
Terms of Appointment	Appointment as Independent Director (Non-Executive) of the Company for a term of 5 consecutive years w.e.f. 25 <sup>th</sup> July, 2025, subject to the approval of the members/shareholders of the Company.	Appointment as Independent Director (Non-Executive) of the Company for a term of 5 consecutive years w.e.f. 25 <sup>th</sup> July, 2025, subject to the approval of the members/shareholders of the Company.	Appointment as Independent Director (Non-Executive) of the Company for a term of 5 consecutive years w.e.f. 25 <sup>th</sup> July, 2025, subject to the approval of the members/shareholders of the Company.
Shareholding of Director in the Company	Nil	Nil	Nil
Relationship between Directors	Not Related	Not Related	Not Related
Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority	Yes, not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Yes, not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Yes, not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Date : 25<sup>th</sup> July, 2025  
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



*Sanjay S. Shah*  
**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**DIN: 01515296**

**Annexure-3**

**The disclosure with regard to appointment of Secretarial Auditor:**

Sr. No.	Disclosure requirement	Details of Secretarial Auditor
(a)	Name of Auditors	M/s. Nishant Pandya & Associates, Practising Company Secretaries
(b)	Reason for change	Appointment
(c)	Date of recommendation & Terms for Appointment	25 <sup>th</sup> July, 2025  Board of Directors in its meeting held on 25 <sup>th</sup> July, 2025 recommended appointment of M/s. Nishant Pandya & Associates, Practising Company Secretaries as Secretarial Auditors of the Company for a term of five (5) consecutive years to conduct the Secretarial Audit for financial years commencing from FY 2025-26 to FY 2029-30 subject to approval of shareholders/members at the ensuing AGM.
(d)	Brief Profile	M/s. Nishant Pandya & Associates, Practising Company Secretaries firm has been Peer Reviewed and Quality Reviewed by the Institute of Company Secretaries of India (ICSI). Mr. Nishant Pandya, Proprietor of M/s. Nishant Pandya & Associates holds degree of B.Com. & ACS. He is a Company Secretary in practice since more than 6 years. He has experience in Corporate Laws & Finance. The firm focusses on providing comprehensive professional services in Corporate Laws and SEBI Regulations.
(e)	Disclosure of relationships between Directors (in case of appointment of a director)	None

**The disclosure with regard to appointment of Cost Auditor:**

Sr. No.	Disclosure requirement	Details of Cost Auditor
(a)	Name of Auditors	M/s Dalwadi & Associates, Cost Accountants
(b)	Reason for change	Appointment / Re- appointment
(c)	Date & Terms of Appointment	25 <sup>th</sup> July, 2025 Appointment /reappointed as Cost Auditors of the Company for the F.Y. 2025-26
(d)	Brief Profile	M/s Dalwadi & Associates, Cost Accountants having qualified Cost & Management Accountants rendering services encompassing, services of Audit & Assurance, Indirect Taxes, Management Advisory Services, Finance & Banking, etc. The partners of the firm have exposure of more than one decade in the field of Cost & Management Accountancy.
(e)	Disclosure of relationships between Directors (in case of appointment of a director)	None

Date : 25<sup>th</sup> July, 2025  
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



*Sanjay S. Shah*  
**SANJAY S. SHAH**  
**MANAGING DIRECTOR**  
**DIN: 01515296**

**Annexure-4**

**Brief Profile of the Auditor appointed:**

<b>Name</b>	<b>Mr. Nimesh Suthar</b>	<b>Mr. Raviraj Karia</b>	<b>Mr. Sudhir Ghule</b>
<b>Designation</b>	Senior Vice President (International Business)	Senior Vice President (Finance & Accounts)	Chief Operating Officer (COO)
<b>Reason for Change</b>	Appointment	Appointment	Appointment
<b>Date of Appointment and term of appointment</b>	July 25, 2025  Terms of Appointment – Full Time Employment	July 25, 2025  Terms of Appointment – Full Time Employment	July 25, 2025  Terms of Appointment – Full Time Employment
<b>Brief Profile (in case of appointment)</b>	<p>Mr. Nimesh Suthar, as Senior Vice President (International Business): an accomplished Pharmacist, have over 25 years of extensive experience in the pharmaceutical industry, including 8 years in the domestic market and 17 years in international business.</p> <p>Before Sakar, he was associated with Baxter, Dr. Reddy's Laboratories, Claris Lifesciences and Troikka Pharmaceuticals. He is experienced with strategic market development with deep cross-cultural insights, regulatory navigation, and partnership building in global pharmaceutical markets covering diverse geographies, including covering both regulated and emerging markets.</p>	<p>Mr. Raviraj Karia is a qualified Chartered Accountant with MBA (Finance), have 17 years of experience with Intas Pharmaceuticals Limited. He was earlier associated with Shalby Limited, Gati Limited, Gujarat Venture Finance Limited (GVFL) and Claris Lifesciences Limited</p> <p>With a hefty 22+ years industry experience of which 19 years in Lifesciences / Healthcare, he has an in depth exposure globally with Pharmaceutical, Clinical/Contract research, Healthcare, Supply chain and Private equity domain. He has domain knowledge of Treasury, Mergers and Acquisitions, In &amp; Out licensing, Internal Audit, Borrowings, Strategic Finance, Corporate Finance, Due Diligences, Procurement and Commercial functions.</p>	<p>Mr. Sudhir Ghule, is a Pharmacist with over three decades of diversified experience with leading organisations that includes Zydus Lifesciences, Cipla, Sun Pharma, Lupin.</p> <p>With an in-depth exposure to pharmaceutical plant operations, he has successfully managed technical and quality functions at assigned levels heading cluster of plant operations with considerable sized employee strength implementing simplification, automation and digitalization to build a robust work culture. He has been pivotal in perceiving and installing technical capabilities to successfully handling stringent regulatory audits multiple times including USFDA, MHRA, TGA.</p>



Disclosure of relationships between directors (in case of appointment of a director)	None	None	None
--	------	------	------

Date : 25<sup>th</sup> July, 2025  
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



*Sanjay S. Shah*  
SANJAY S. SHAH  
MANAGING DIRECTOR  
DIN: 01515296